(CercleFinance.com) – Innate Pharma announces that the first patient has been treated in the phase 2 dose expansion of the study led by Sanofi, evaluating SAR443579 / IPH6101 as monotherapy to treat various hematological cancers for which medical needs remain unmet .
The pharmaceutical company specifies that the cancers studied include relapsed/refractory acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, or high-risk myelodysplastic syndrome.
This progress in the trial triggered a milestone payment from Sanofi to Innate of four million euros. Resulting from a collaboration between the two groups, SAR443579 obtained Fast Track status from the US FDA for the treatment of AML.